HOME >> MEDICINE >> NEWS
Heart Experts Call For Action Against Missed Opportunities To Prevent Heart Disease In Women

DALLAS, April 30 -- The American Heart Association and American College of Cardiology called today for action against missed opportunities to reduce women's risk of coronary heart disease, the No. 1 killer of both men and women.

The scientific statement, produced in collaboration with four other professional health organizations, provides updated recommendations for closing what the AHA and ACC say is the wide gap between what is known to prevent heart disease in women and what actually is being done.

The scientific statement, "Guide to Preventive Cardiology for Women," which is published today in the Journal of the American College of Cardiology and will appear in the May 11 issue of Circulation: Journal of the American Heart Association, was produced in collaboration with the American Medical Women's Association, American College of Nurse Practitioners, American College of Obstetricians and Gynecologists, and Canadian Cardiovascular Society. Among the recommendations:

  • A statin or cholesterol-lowering drug should be considered instead of hormone replacement therapy as the first line of drug therapy for lowering high blood levels of cholesterol in postmenopausal women.

  • The target blood level of high-density lipoprotein, HDL, the "good" cholesterol, should be higher than national recommendations.

  • Diabetes increases a woman's risk of heart disease three to seven times, compared with a two- to three-fold risk increase in men. Thus, it is imperative to step up efforts to identify women at risk and provide them with effective treatment.
"Although more women die from coronary heart disease than from cancer or any other disease, we are missing many opportunities to reduce the risk of heart disease in women," says Lori Mosca, M.D., Ph.D., chair of the consensus panel that developed the statement and chair of the AHA's "Take Wellness to Heart" campaign to inform women about reducing their risk for heart d
'"/>

Contact: Cathy Yarbrough
cathyy@heart.org
214-706-1340
American Heart Association
30-Apr-1999


Page: 1 2 3

Related medicine news :

1. The European Society of Cardiology launches Women at Heart
2. Heart surgeons publish death rates
3. Heart attack treatment gap may be closing for women
4. The Larry King Cardiac Foundation presents The Changing Face of Heart Disease on Feb. 2
5. Brenner Childrens Hospital named to NIH Pediatric Heart Network
6. Heart patients treated by non-cardiologists less likely to receive medications
7. Heart failure patients treated for diabetes with insulin have increase in mortality
8. New research results: Heart jacket shown to be effective
9. Heart surgery patients receive less aggressive discharge care
10. Heart attack, stroke risk overlooked in diabetics
11. Heart arrhythmias easily treated, yet few know risks

Post Your Comments:
(Date:8/31/2015)... ... August 31, 2015 , ... For 12 years, since 2004, the ... 26th as Mesothelioma Awareness Day . On this day, and in the weeks ... of becoming involved and helping the cause. , “One of the ways a person ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company The Mood ... to raise money and awareness for breast and ovarian health. During September ... incandescent Mood-lite sold to Bright Pink® to encourage households, dorms, and offices around ...
(Date:8/31/2015)... ... 31, 2015 , ... The Brooks Group, a global sales ... department devoted to helping organizations identify and keep the best talent both inside ... Brooks Group believes in offering a solution that goes beyond simply providing assessments ...
(Date:8/31/2015)... ... August 31, 2015 , ... ERT, a leading global provider ... solutions will demonstrate multiple prototypes from its Innovation Lab during its 8th Annual ... the only European event dedicated to providing case studies and pragmatic information on ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... certifies products for the water, food, health sciences and consumer goods industries, has ... for their advanced iron filtration media, Pro-OX Manganese Dioxide. , Developed by a ...
Breaking Medicine News(10 mins):Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 2Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 3Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 2Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 3
(Date:8/31/2015)... PRINCETON, N.J. , Aug. 31, 2015  /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today it has ... by the Data Review Committee (DRC) earlier this ... SGX942.  SGX942 is a first-in-class innate defense regulator ...
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, ... on the emerging field of regenerative medicine, today ... at Chicago -based Rush University ... evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte ... and motor complete cervical spinal cord injury (SCI). ...
(Date:8/31/2015)... and STAMFORD, Conn. , Aug. ... of Eisai Co., Ltd., and Purdue Pharma L.P. announced ... agreement for the development and commercialization of Eisai,s clinical ... antagonist entering Phase III clinical development for the treatment ... the agreement, Eisai and Purdue Pharma will share the ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
Cached News: